A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines

Middelberg, Anton P.J., Rivera-Hernandez, Tania, Wibowo, Nani, Lua, Linda H.L., Fan, Yuanyuan, Magor, Graham, Chang, Cindy, Chuan, Yap P., Good, Michael F. and Batzloff, Michael R. (2011) A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine, 29 41: 7154-7162. doi:10.1016/j.vaccine.2011.05.075

Author Middelberg, Anton P.J.
Rivera-Hernandez, Tania
Wibowo, Nani
Lua, Linda H.L.
Fan, Yuanyuan
Magor, Graham
Chang, Cindy
Chuan, Yap P.
Good, Michael F.
Batzloff, Michael R.
Title A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines
Journal name Vaccine   Check publisher's open access policy
ISSN 0264-410X
Publication date 2011-09-22
Sub-type Article (original research)
DOI 10.1016/j.vaccine.2011.05.075
Volume 29
Issue 41
Start page 7154
End page 7162
Total pages 9
Place of publication United Kingdom
Publisher Elsevier Ltd
Collection year 2012
Language eng
Abstract Studies on a platform technology able to deliver low-cost viral capsomeres and virus-like particles are described. The technology involves expression of the VP1 structural protein from murine polyomavirus (MuPyV) in Escherichia coli, followed by purification using scaleable units and optional cell-free VLP assembly. Two insertion sites on the surface of MuPyV VP1 are exploited for the presentation of the M2e antigen from influenza and the J8 peptide from Group A Streptococcus (GAS). Results from testing on mice following subcutaneous administration demonstrate that VLPs are self adjuvating, that adding adjuvant to VLPs provides no significant benefit in terms of antibody titre, and that adjuvanted capsomeres induce an antibody titre comparable to VLPs but superior to unadjuvanted capsomere formulations. Antibodies raised against GAS J8 peptide following immunization with chimeric J8-VP1 VLPs are bactericidal against a GAS reference strain. E. coli is easily and widely cultivated, and well understood, and delivers unparalleled volumetric productivity in industrial bioreactors. Indeed, recent results demonstrate that MuPyV VP1 can be produced in bioreactors at multi-gram-per-litre levels. The platform technology described here therefore has the potential to deliver safe and efficacious vaccine, quickly and cost effectively, at distributed manufacturing sites including those in less developed countries. Additionally, the unique advantages of VLPs including their stability on freeze drying, and the potential for intradermal and intranasal administration, suggest this technology may be suited to numerous diseases where adequate response requires large-scale and low-cost vaccine manufacture, in a way that is rapidly adaptable to temporal or geographical variation in pathogen molecular composition.
Keyword Influenza
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2012 Collection
Australian Institute for Bioengineering and Nanotechnology Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 47 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 49 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 14 Oct 2011, 08:48:16 EST by Linda Lua on behalf of Aust Institute for Bioengineering & Nanotechnology